nach oben

Die Ophthalmologie

Erschienen in:

01.05.2007 | Leitthema

Systemische Immunsuppressiva nach perforierender Keratoplastik

verfasst von: PD Dr. A. Reis, F. Birnbaum, T. Reinhard

Erschienen in: Die Ophthalmologie | Ausgabe 5/2007

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die immunologische Abstoßungsreaktion ist der wichtigste Grund für ein Transplantatversagen nach Hornhauttransplantation. Ohne systemische Immunsuppression kommt es in einer Hochrisikosituation in über 50% der Fälle zu einer Eintrübung des Transplantats innerhalb des ersten postoperativen Jahres. Die klonale Expansion von alloreaktiven Lymphozyten findet in lymphoiden Organen statt. Da topische Steroide die sekundären lymphatischen Gewebe nicht erreichen und auch systemische Steroide nicht ausreichend die klonale Expansion von aktivierten T-Zellen unterdrücken, ist der Einsatz von systemischen Immunsuppressiva unumgänglich, um ein klares Transplantatüberleben zu erreichen. Es ist allerdings besonders nach Hochrisikokeratoplastik, einer nicht lebensrettenden Transplantation wichtig, die Vor- und Nachteile einer immunsuppressiven Therapie abzuwägen.

Allison A, Hovi R, Watts A et al. (1977) The role of de novo purine synthesis in lymphocyte transformation. Ciba Found Symp 48: 207PubMed

Benelli U, Lepri A, Del-Tacca M et al. (1996) FK-506 delays corneal graft. J Ocul Pharmacol Ther 12: 425–431PubMed

Birnbaum F, Reinhard T, Bohringer D et al. (2005) Endothelial cell loss after autologous rotational keratoplasty. Graefes Arch Clin Exp Ophthalmol 243: 57–59CrossRefPubMed

Brattstrom C, Tyden G, Sawe J et al. (1996) A randomized, double-blind, placebo-controlled study to determine safety, tolerance, and preliminary pharmacokinetics of ascending single doses of orally administered sirolimus (rapamycin) in stable renal transplant recipients. Transplant Proc 28: 985–986PubMed

Bussutil RW, Holt CD (1997) Tacrolimus (FK506) is superior to cyclosporine in liver transplantation. Transplant Proc 29: 534–538CrossRefPubMed

Chen YF, Gebhardt BM, Reidy JJ et al. (1990) Cyclosporine-containing collagen shields suppress corneal allograft rejection. Am J Ophthalmol 109: 132–137PubMed

Crowe A, Lemaire M (1998) In vitro and in situ absorption of SDZ-RAD using a human intestinal cell line (Caco-2) and a single pass perfusion model in rats: comparison with rapamycin. Pharm Res 15: 1666–1672CrossRefPubMed

Deierhoi M, Sollinger H, Diethelm A et al. (1993) One-year follow-up results of a phase 1 trial of mycophenolate mofetil (RS-61443) in cadaveric renal transplantation. Transplant Proc 25: 693PubMed

Dickey JB, Cassidy EM, Bouchard CS (1993) Periocular FK-506 delays allograft rejection in rat penetrating keratoplasty. Cornea 12: 204–207CrossRefPubMed

10.

Eisen HJ, Tuzcu EM, Dorent R et al. (2003) Everolimus for the Prevention of Allograft Rejection and Vasculopathy in Cardiac-Transplant Recipients. N Engl J Med 349: 847–858CrossRefPubMed

11.

European Mycophenolate Mofetil Cooperative Study Group (1995) Placebo controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for the prevention of acute rejection. The Lancet 345: 1321–1325

12.

Mayer K, Birnbaum F, Reinhard T et al. (2004) FTY720 prolongs clear corneal allograft survival with a differential effect on different lymphocyte populations. Br J Ophthalmol 88: 915–919CrossRefPubMed

13.

Hikita N, Lopez JS, Chan C et al. (1997) Use of topical FK506 in a corneal graft rejection model in lewis rats. Invest Ophthalmol Vis Sci 38: 901–909PubMed

14.

Hill JC, Maske R (1988) An animal model for corneal graft rejection in high-risk keratoplasty. Transplantation 46: 26–30CrossRefPubMed

15.

Hill JC (1995) Systemic cyclosporine in high-risk keratoplasty: long-term results. Eye 9: 422–428 PubMed

16.

Hoffmann F, Wiederholt M (1986) Topical cyclosporin A in the treatment of corneal graft reaction [editorial]. Cornea 5: 129PubMed

17.

Kino T, Hatayama H, Hashimoto M et al. (1987) FK-506, a novel immunosuppressant isolated from Streptomyces: 1: Fermentation, isolation, and physio-chemical and biological characteristics. J Antibiot 40: 1249–1255PubMed

18.

Lakkis FG, Arakelov A, Koniecny BT et al. (2000) Immunologic „ignorance“ of vascularized organ transplants in the absence of secondary lymphoid tissue. Nat Med 6: 686–688CrossRefPubMed

19.

Mayer K, Reinhard T, Reis A et al. (2003) Synergistic antiherpetic effect of acyclovir and mycophenolate mofetil following keratoplasty in patients with herpetic eye disease: first results of a randomised pilot study. Graefes Arch Clin Exp Ophthalmol 241: 1051–1054CrossRefPubMed

20.

21.

Mills RA, Jones DB, Winkler CR et al. (1995) Topical FK-506 prevents experimental corneal allograft rejection. Cornea 14: 157–160CrossRefPubMed

22.

Minamoto A, Sakata H, Okada K et al. (1995) Suppression of corneal graft rejection by subconjunctival injection of FK-506 in a rat model of penetrating keratoplasty. Jpn J Ophthalmol 39: 12–19PubMed

23.

Morris R, Hoyt E, Murphy P (1990) Mycophenolic acid morpholinoethylester (RS-61443) is a new immunosuppressant that prevents and halts heart allograft rejection by selevtive inhibition of T- and B-cell purine synthesis. Transplant Proc 22: 1659PubMed

24.

Morris RE, Huang X, Gregory CR et al. (1995) Berry-Studies in experimental models of chronic rejection: use of rapamycin (sirolimus) and isoxazole derivatives (leflunomide and its analogue) for the suppression of graft vascular disease and obliterative bronchiolitis. Transplant Proc 27: 2068–2069PubMed

25.

Murgia MG, Jordan S, Kahan BD (1996) The side effect profile of sirolimus: a phase I study in quiescent cyclosporine-prednisone-treated renal transplant patients. Kidney Int 49: 209–216PubMed

26.

Olsen TW, Benegas NM, Joplin AC et al. (1994) Rapamycin inhibits corneal allograft rejection and neovascularization. Arch Ophthalmol 112: 1471–1475PubMed

27.

Otto Ch, Ulrichs K (2004) The immunology of allograft rejection. Tx Med 16: 158–171

28.

Perry HD, Donnenfeld ED, Acheampong A et al. (1998) Topical Cyclosporine A in the management of postkeratoplasty glaucoma and corticosteroid-induced ocular hypertension (CIOH) and the penetration of topical 0.5% cyclosporine A into the cornea and anterior chamber. CLAO J 24: 159–165 PubMed

29.

Reinhard T, Bohringer D, Enzmann J et al. (2004) HLA class I/II matching and chronic endothelial cell loss in penetrating normal risk keratoplasty. Acta Ophtahmol Scand 82: 13–18CrossRef

30.

Reinhard T, Kontopoulos T, Wernet P et al. (2004) Long-term results of homologous penetrating limbokeratoplasty in total limbal stem cell insufficiency after chemical/thermal burns. Ophthalmologe 101: 682–687CrossRefPubMed

31.

Reinhard T, Moller M, Sundmacher R (1999) Penetrating keratoplasty in patients with atopic dermatitis with and without systemic cylocsporin A. Cornea 18: 645–651 CrossRefPubMed

32.

Reinhard T, Sundmacher R, Godehardt E et al. (1997) [Preventive systemic cyclosporin A after keratoplasty at increased risk for immune reactions as the only elevated risk factor] Systemische Cyclosporin-A-Prophylaxe nach Keratoplastiken mit erhohtem Risiko fur Immunreaktionen als einzigem erhohten Risikofaktor. Ophthalmologe 94: 496–500CrossRefPubMed

33.

Reinhard T, Sundmacher R (1996) Local cyclosporin A therapy in Thygeson superficial punctate keratitis–a pilot study. Klin Monatsbl Augenheilkd 209: 224–227PubMed

34.

Reinhard T, Sundmacher R (1992) Perforating keratoplasty in endogenous eczema. An indication for systemic cyclosporin A–a retrospective study of 18. Klin Monatsbl Augenheilkd 201: 159–163 PubMed

35.

Reinhard T, Sundmacher R (1999) Topical Cyclosporin A in Thygeson‚s superficial punctate keratitis. Graefes Arch Clin Exp Ophthalmol 237: 109–112CrossRefPubMed

36.

Reis A, Megahed M, Reinhard T et al. (2001). RAD, a new immunosuppressive macrolide in murine corneal transplantation. Graefes Arch Clin Exp Ophthalmol 239: 689–692PubMed

37.

Reis A, Megahed M, Reinhard T et al. (2002) Synergism of RAD and cyclosporin A in prevention of acute rat corneal allograft rejection. Cornea 21: 81–84CrossRefPubMed

38.

Reis A, Megahed M, Reinhard T et al. (2000) Coadministration of the new macrolide immunosuppressant RAD and mycophenolate mofetil in experimental corneal transplantation. Transplantation 70: 1397–1401CrossRefPubMed

39.

Reis A, Reinhard T, Sundmacher R et al. (1998) [Mycophenolatemofetil in ocular immunological disorders. A survey of the literature with 3 case reports], Mycophenolatmofetil (CellCept) bei okularen immunologischen Storungen. Literaturubersicht mit 3 Kasuistiken. Klin Monatsbl Augenheilkd 213: 257–261 PubMed

40.

Reis A, Reinhard T, Sundmacher R et al. (1998) Effect of mycophenolate mofetil, cyclosporin A, and both in combination in a murine corneal graft rejection model. Br J Ophthalmol 82: 700–703PubMed

41.

Reis A, Reinhard T, Sundmacher R et al. (1998) A Comparative Investigation of the Effect of FK506 (Prograf®) and Cyclosporin A (Sandimmun®, CSA) In Murine Corneal Transplantation. Graefes Arch Clin Exp Ophthalmol 236: 785–789CrossRefPubMed

42.

Reis A, Reinhard T, Sundmacher R et al. (1998) FK506 and Mycophenolatemofetil: Two novel immunosuppressants in murine corneal transplantation. Transpl Proc 30: 44

43.

Reis A, Reinhard T, Voiculescu A et al. (1999) Mycophenolatemofetil versus Cyclosporin A in high-risk keratoplasty patients: A prospectively randomized clinical trial. Br J Ophthalmol 83: 1268–1271PubMed

44.

Sawada S, Suzuki G, Kawase Y et al. (1987) Novel immunosuppressive agent, FK-506: In vitro effects on the cloned T cell activation. J Immunol 40: 1249–1255

45.

Schmitz K, Hitzer S, Behrens-Baumann W (2002) Immune suppression by combination therapy with basiliximab and cyclosporin in high risk keratoplasty. A pilot study. Ophthalmologe 99: 38–45CrossRefPubMed

46.

Schuurman HJ, Schuler W, Ringers J et al. (1998) The macrolide SDZ RAD is efficacious in a nonhuman primate model of allotransplantation. Transplant Proc 30: 2198–2199CrossRefPubMed

47.

Simmons WD, Rayhill SC, Sollinger HW (1997) Preliminary risk-benefit assessment of mycophonlate mofetil in transplant rejection. Drug Safety 17: 75–92PubMed

48.

Sloper CM, Powell RJ, Dua HS (2001) Tacrolimus (FK506) in the management of high-risk corneal and limbal grafts. Ophthalmology 108: 1838–1844CrossRefPubMed

49.

Streilein JW, Okamoto S, Sano Y, Taylor AW (2000) Neural control of ocular immune privilege. Ann NY Acad Sci 917: 297–306PubMed

50.

The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group (1996) A blinded, randomized clinical trial of mycophnolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 61: 1029–1037PubMed

51.

Thompson P, Xu D, Brunette I, Chen H (1998) Combined effect of rapamycin and cyclosporine in the prevention of rat corneal allograft rejection. Transplant Proc 30: 1033–1035 CrossRefPubMed

52.

Vu MD, Qi S, Xu D et al. (1998). Synergistic effects of mycophenolate mofetil and sirolimus in prevention of acute heart, pancreas, and kidney allograft rejection and in reversal of ongoing heart allograft rejection in the rat. Transplantation 66: 1575–1580 CrossRefPubMed

53.

Woodle ES, Thistlethwaite JR, Gordon JH (1996) For the FK506 Kidney Transplant Rescue Study Group: A multicenter trial of FK506 (tacrolimus) therapy in refractory acute renal allograft rejection. Transplantation 62: 594–599CrossRefPubMed

54.

Yoshimura N, Matsui S, Hamashima T et al. (1989). Effects of a new immunosuppressive agent, FK-506, on human lymphocyteresponsiveness in vitro: 1: Inhibition of expression of alloantigen-activated suppressor cells, as well as induction of alloreactivity. Transplantation 47: 351–356PubMed

Titel: Systemische Immunsuppressiva nach perforierender Keratoplastik
verfasst von: PD Dr. A. Reis
F. Birnbaum
T. Reinhard
Publikationsdatum: 01.05.2007
Verlag: Springer-Verlag
Erschienen in: Die Ophthalmologie / Ausgabe 5/2007
Print ISSN: 2731-720X
Elektronische ISSN: 2731-7218
DOI: https://doi.org/10.1007/s00347-007-1517-x

Neu im Fachgebiet Augenheilkunde

08.04.2024 | Therapieverfahren in der Augenheilkunde | CME

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Systemische Immunsuppressiva nach perforierender Keratoplastik

Zusammenfassung

Neu im Fachgebiet Augenheilkunde

Ophthalmika in der Schwangerschaft

Operative Therapie und Keimnachweis bei endogener Endophthalmitis

Bakterielle endogene Endophthalmitis

So erreichen Sie eine bestmögliche Wundheilung der Kornea

Update Augenheilkunde

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2007

Akute Visusminderung am Oculus ultimus

Wiedereröffnungsrate von Makulaforamina nach Kataraktoperation

Schmerzlose Akanthamöbenkeratitis

Lokale Immunsuppressiva nach perforierender Keratoplastik

Vergleich von resorbierbaren und nichtresorbierbaren skleralen Implantaten bei tiefer Sklerektomie (SK-Gel und T-Flux)

Unklare Optikusatrophie

Neu im Fachgebiet Augenheilkunde

Ophthalmika in der Schwangerschaft

Operative Therapie und Keimnachweis bei endogener Endophthalmitis

Bakterielle endogene Endophthalmitis

So erreichen Sie eine bestmögliche Wundheilung der Kornea

Update Augenheilkunde